These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23755896)

  • 1. Genetic modification of hypertension by sGCα1.
    Sips PY; Buys ES
    Trends Cardiovasc Med; 2013 Nov; 23(8):312-8. PubMed ID: 23755896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.
    Buys ES; Sips P; Vermeersch P; Raher MJ; Rogge E; Ichinose F; Dewerchin M; Bloch KD; Janssens S; Brouckaert P
    Cardiovasc Res; 2008 Jul; 79(1):179-86. PubMed ID: 18339647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
    Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
    Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
    El-Sehemy A; Chang AC; Azad AK; Gupta N; Xu Z; Steed H; Karsan A; Fu Y
    Cell Signal; 2013 Dec; 25(12):2780-7. PubMed ID: 24041655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
    Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
    Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model.
    Crassous PA; Couloubaly S; Huang C; Zhou Z; Baskaran P; Kim DD; Papapetropoulos A; Fioramonti X; Durán WN; Beuve A
    Am J Physiol Heart Circ Physiol; 2012 Sep; 303(5):H597-604. PubMed ID: 22730391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient mice.
    Buys ES; Raher MJ; Kirby A; Shahid M; Baron DM; Hayton SR; Tainsh LT; Sips PY; Rauwerdink KM; Yan Q; Tainsh RE; Shakartzi HR; Stevens C; Decaluwé K; Rodrigues-Machado Mda G; Malhotra R; Van de Voorde J; Wang T; Brouckaert P; Daly MJ; Bloch KD
    J Clin Invest; 2012 Jun; 122(6):2316-25. PubMed ID: 22565307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
    Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.
    Groneberg D; König P; Wirth A; Offermanns S; Koesling D; Friebe A
    Circulation; 2010 Jan; 121(3):401-9. PubMed ID: 20065162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
    Wobst J; Rumpf PM; Dang TA; Segura-Puimedon M; Erdmann J; Schunkert H
    Circ J; 2015; 79(3):463-9. PubMed ID: 25746521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-sensitive hypertension associated with soluble guanylate cyclase-α1 deficiency is mediated by 20-HETE.
    Dordea AC; Vandenwijngaert S; Garcia V; Tainsh RE; Nathan DI; Allen K; Raher MJ; Tainsh LT; Zhang F; Lieb WS; Mikelman S; Kirby A; Stevens C; Thoonen R; Hindle AG; Sips PY; Falck JR; Daly MJ; Brouckaert P; Bloch KD; Bloch DB; Malhotra R; Schwartzman ML; Buys ES
    Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1790-800. PubMed ID: 27199131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.
    Marro ML; Peiró C; Panayiotou CM; Baliga RS; Meurer S; Schmidt HH; Hobbs AJ
    J Biol Chem; 2008 Jul; 283(29):20027-36. PubMed ID: 18474600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders.
    Wilkins MR; Aldashev AA; Wharton J; Rhodes CJ; Vandrovcova J; Kasperaviciute D; Bhosle SG; Mueller M; Geschka S; Rison S; Kojonazarov B; Morrell NW; Neidhardt I; Surmeli NB; Aitman TJ; Stasch JP; Behrends S; Marletta MA
    Circ Cardiovasc Genet; 2014 Dec; 7(6):920-9. PubMed ID: 25373139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice.
    Thoonen R; Cauwels A; Decaluwe K; Geschka S; Tainsh RE; Delanghe J; Hochepied T; De Cauwer L; Rogge E; Voet S; Sips P; Karas RH; Bloch KD; Vuylsteke M; Stasch JP; Van de Voorde J; Buys ES; Brouckaert P
    Nat Commun; 2015 Oct; 6():8482. PubMed ID: 26442659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and regulation of soluble guanylate cyclase.
    Derbyshire ER; Marletta MA
    Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.
    Liu Y; Dillon AR; Tillson M; Makarewich C; Nguyen V; Dell'Italia L; Sabri AK; Rizzo V; Tsai EJ
    J Mol Cell Cardiol; 2013 Jul; 60():72-83. PubMed ID: 23567617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.
    Rukoyatkina N; Walter U; Friebe A; Gambaryan S
    Thromb Haemost; 2011 Nov; 106(5):922-33. PubMed ID: 21800013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted genomic disruption of h-ras induces hypotension through a NO-cGMP-PKG pathway-dependent mechanism.
    Chamorro-Jorganes A; Grande MT; Herranz B; Jerkic M; Griera M; Gonzalez-Nuñez M; Santos E; Rodriguez-Puyol D; Lopez-Novoa JM; Rodriguez-Puyol M
    Hypertension; 2010 Sep; 56(3):484-9. PubMed ID: 20679183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.
    Cai C; Chen SY; Zheng Z; Omwancha J; Lin MF; Balk SP; Shemshedini L
    Oncogene; 2007 Mar; 26(11):1606-15. PubMed ID: 16964290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.